Claims
- 1. A method of treating a human or animal patient suffering from an insulin resistance syndrome, said method comprising the administration to the patient of an effective insulin resistance reducing amount of magnesium vanadate.
- 2. A method according to claim 1 wherein said syndrome is selected from the group consisting of diabetes mellitus, obesity, dyslipidemia and hypertension.
- 3. A method according to claim 2 wherein said syndrome is diabetes mellitus.
- 4. A method according to claim 1 wherein said patient is human.
- 5. A method according to claim 1 wherein said effective amount of magnesium vanadate is from about 2 to about 60 miligrams per kilogram of patient body weight per day.
- 6. A method according to claim 5 wherein said effective amount is from about 10 to about 40 milligrams per kilogram of patient body weight per day.
- 7. A method according to claim 5 wherein said effective amount is administered to the patient in one to four divided doses.
- 8. A method according to claim 1 wherein the magnesium vanadate is administered to the patient in a pharmaceutical composition which additionally includes at least one pharmaceutically acceptable inert ingredient.
- 9. A method according to claim 8 wherein said pharmaceutical composition is administered orally.
- 10. A method according to claim 9 wherein said pharmaceutical composition is an oral dosage form selected from the group consisting of tablets, coated tablets, capsules, caplets, sustained release tablets, capsules or caplets, liquids and elixirs.
- 11. A method according to claim 8 wherein said pharmaceutical composition is administered parenterally, transdermally or transmucosally.
- 12. A method according to claim 8 wherein said composition includes an additional pharmaceutically active ingredient.
- 13. A method according to claim 12 wherein said additional active ingredient is selected from the group consisting of hypoglycemic agents and antihypertensive agents.
- 14. A method according to claim 13 wherein said additional active ingredient is insulin.
Parent Case Info
This application is a continuation of Ser. No. 08/089,953, filed Jul. 12, 1993, now abandoned.
US Referenced Citations (5)
Non-Patent Literature Citations (5)
Entry |
Rossetti et al. Diabetes, 39:1243-1250 (1990). |
Rossetti et al. J. Clin. Invest., 84:892-899 (1989). |
Cordera et al. Endocrinology, 126:2177-2183 (1990). |
Blondel et al. Am. J. Physiol., 258:E459-E467 (1990). |
Serradas et al. Pancreas, 6:54-62 (1991). |
Continuations (1)
|
Number |
Date |
Country |
Parent |
89953 |
Jul 1993 |
|